Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2004

01-03-2004 | Original Article

Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions

Authors: C. De Cicco, G. Trifirò, M. Intra, G. Marotta, A. Ciprian, A. Frasson, G. Prisco, A. Luini, G. Viale, G. Paganelli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2004

Login to get access

Abstract

The aim of this study was to evaluate the feasibility of sentinel node (SN) biopsy in occult breast lesions with different radiopharmaceuticals and to establish the optimal lymphoscintigraphic method to detect both occult lesions and SNs (SNOLL: sentinel node and occult lesion localisation). Two hundred and twenty-seven consecutive patients suspected to have clinically occult breast carcinoma were enrolled in the study. In addition to the radioguided occult lesion localisation (ROLL) procedure, using macroaggregates of technetium-99m labelled human serum albumin (MAA) injected directly into the lesion, lymphoscintigraphy was performed with nanocolloids (NC) injected in a peritumoral (group I) or a subdermal site (group II). In group III, a sole injection of NC was done into the lesion in order to perform both ROLL and SNOLL. Overall, axillary SNs were identified in 205 of the 227 patients (90.3%). In 12/62 (19.4%) patients of group I and 9/79 (11.4%) patients of group III, radioactive nodes were not visualised, whereas SNs were successfully localised in 85 of 86 patients of group II (P<0.001). Pathological findings revealed breast carcinoma in 148/227 patients (65.2%) and benign lesions in 79 (34.8%). A total of 131 axillary SNs were removed in 118 patients with breast carcinoma; intraoperative examination of the SNs revealed metastatic involvement in 16 out of 96 cases of invasive carcinoma (16.7%). It is concluded that the combination of the ROLL procedure with direct injection of MAA into the lesion and lymphoscintigraphy performed with subdermal injection of radiocolloids represents the method of choice for accurate localisation of both non-palpable lesions and SNs.
Literature
1.
Franceschi D, Crowe J, Zollinger R, et al. Biopsy of the breast for mammographically detected lesions. Surg Gynecol Obstet 1990; 171:449–455.PubMed
2.
Goedde TA, Frykberg ER, Crump JM, Lay SF, Turetsky DB, Linden SS. The impact of mammography on breast biopsy. Am Surg 1992; 58:661–666.PubMed
3.
Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C, Intra M, Tosi G, Scarpa D. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368–373.CrossRefPubMed
4.
Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553–2559.PubMed
5.
Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542–2551.PubMed
6.
Paganelli G, De Cicco C, Luini A, Cassano E, Pizzamiglio M, Fiorenza M, Galimberti V, Zurrida S, Veronesi U. Radioguided surgery in non-palpable breast lesions. Eur J Nucl Med 1997; 24:893.
7.
Luini A, Zurrida S, Galimberti V, Paganelli G. Radioguided surgery of occult breast lesions. Eur J Cancer 1998; 34:204–205.PubMed
8.
De Cicco C, Pizzamiglio M, Trifiro G, Luini A, Ferrari M, Prisco G, Galimberti V, Cassano E, Viale G, Intra M, Veronesi P, Paganelli G. Radioguided occult lesion localisation (ROLL) and surgical biopsy in breast cancer. Technical aspects. Q J Nucl Med 2002 Jun; 46:145–151.
9.
Feggi L, Basaglia E, Corcione S, Querzoli P, Soliani G, Ascanelli S, Prandini N, Bergossi L, Carcoforo P. An original approach in the diagnosis of early breast cancer: use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation. Eur J Nucl Med 2001; 28:1589–1596.PubMed
10.
Barros A, Cardoso MA, Sheng PY, Costa PA, Pelizon C. Radioguided localisation of non-palpable breast lesions and simultaneous sentinel lymph node mapping. Eur J Nucl Med Mol Imaging 2002; 29:1561–1565.CrossRefPubMed
11.
WHO. Histological typing of breast tumours, 2nd edn. International Histological Classification of Tumours N 2. Geneva: WHO, 1991.
12.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335–339.PubMed
13.
Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995; 75:2507–2517.PubMed
14.
Luini A, Zurrida S, Paganelli G, Galimberti V, Sacchini V, Monti S, Veronesi P, Viale G, Veronesi U. Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg 1999; 86:522–525.CrossRefPubMed
15.
Gennari R, Galimberti V, De Cicco C, Zurrida S, Zerwes F, Pigatto F, Luini A, Paganelli G, Veronesi U. Use of technetium-99m-labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions. J Am Coll Surg 2000; 190:692–698.PubMed
16.
Valdes-Olmos RA, Jansen L, Hoefnagel CA, Nieweg OE, Muller SH, Rutgers EJ, Kroon BB. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med 2000; 41:1500–1506.PubMed
17.
Cremonesi M, Ferrari M, Sacco E, Rossi A, De Cicco C, Leonardi L, Chinol M, Luini A, Galimberti V, Tosi G, Veronesi U, Paganelli G. Radiation protection in radioguided surgery of breast cancer. Nucl Med Commun 1999; 20:919–924.PubMed
Metadata
Title
Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions
Authors
C. De Cicco
G. Trifirò
M. Intra
G. Marotta
A. Ciprian
A. Frasson
G. Prisco
A. Luini
G. Viale
G. Paganelli
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1390-z

Other articles of this Issue 3/2004

European Journal of Nuclear Medicine and Molecular Imaging 3/2004 Go to the issue

Erratum

Abstracts, Poster Presentations P22 - P35

Original Article

Kinetics of [11C]choline uptake in prostate cancer: a PET stydy

Molecular Imaging

Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake

Short Communication

Monitoring of a new approach of immunotherapy with allogenic 111In-labelled NK cells in patients with renal cell carcinoma

Original Article

Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition

Editorial

Is the future of nuclear medicine written in the genes?